Table 1.
Clinical features of the cohort at baseline.
| Total (N = 160) | Conventional (N = 97) | FTA (n = 63) | P-value | |
|---|---|---|---|---|
| Age at diagnosis, mean (S.D.), years | 72.4 (8.2) | 70.6 (8.2) | 75.1 (7.6) | <0.001 |
| Female, n (%) | 120 (75) | 77 (79.4) | 43 (68.3) | 0.1 |
| Previous PMR, n (%) | 31 (19.4) | 15 (15.5) | 16 (25.4) | 0.1 |
| Symptom latency, median (IQR), days | 46 (15–101) | 62 (20–122) | 33 (15–83) | 0.04 |
| Symptoms latency of patients with PVL, median (IQR), days | 14 (8–65) | 23 (12–96) | 7 (4–10) | 0.02 |
| Comorbidities | ||||
| Coronary heart disease | 15 (10.1) | 9 (9.4) | 6 (11.3) | 0.7 |
| Dyslipidaemia | 30 (20.1) | 18 (18.8) | 12 (22.6) | 0.6 |
| Diabetes mellitus | 18 (12.1) | 14 (14.6) | 4 (7.5) | 0.2 |
| Stroke | 14 (9.4) | 11 (11.5) | 3 (5.7) | 0.2 |
| Peripheral artery disease | 7 (4.7) | 5 (5.2) | 2 (3.8) | 0.2 |
| Hypertension | 85 (57.0) | 53 (55.2) | 32 (60.4) | 0.5 |
| Heart failure | 5 (3.4) | 1 (1.0) | 4 (7.5) | 0.03 |
| Other comorbidities | 102 (68.5) | 73 (76.0) | 39 (73.6) | 0.7 |
| No comorbidities | 18 (12.1) | 16 (16.7) | 2 (3.8) | 0.02 |